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www.cdatm.orgAbstractObjective: Recently, several cohort studies suggested a positive relationship between serum uric acid (SUA) and type 2 diabetes
mellitus (T2DM), which is inconsistent with the results of functional research. Our aim was to further evaluate this correlation by
conducting a systematic review.
Methods: Computerized literature searches of the Medline database, EMBASE database, and PubMed were used to evaluate
the relationship between SUA and T2DM in cohort studies. Cochran's Q and I2 statistics were used to evaluate heterogeneity
among studies, and pooled relative risk (RR) and odds ratio (OR) with 95% confidence intervals (CIs) were calculated using
random-effects and fixed-effects models. The summary RR and OR of per 1 mg/ml-SUA increase were calculated separately
because of their different epidemiological implications and calculation methods. Additionally, sensitivity analysis, stratified
analysis, meta-regression, and multiple meta-regression were applied to investigate the heterogeneity among studies.
Results: A total of 970 articles were retrieved from the searches. Sixteen publications of cohort studies containing 61,714
participants were included. The pooled RR was 1.131 (95% CI: 1.084e1.179) with significant heterogeneity among studies
(I2 ¼ 51.9%, P ¼ 0.018). Adjusted RR to evaluate the stability of the relationship between SUA and T2DM in the
sensitivity analysis was similar (RR ¼ 1.140, 95% CI: 1.087e1.197), with statistically significant heterogeneity
(I2 ¼ 54.5%, P ¼ 0.015). Stratified analysis and meta-regression showed that the positive relationship remained irrespective
of age, sex, region, and adjustment for confounding factors including body mass index, fasting blood glucose, systolic blood
pressure, diastolic blood pressure, alcohol consumption, smoking, blood cholesterol, waist circumference, fatty liver, and
drugs affecting SUA.* Corresponding author. Fax: þ86 25 86527613.
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82 Y.-L. Xu et al. / Chronic Diseases and Translational Medicine 2 (2016) 81e91Conclusion: Although SUA is independently associated with development of T2DM, insulin resistance increased as the baseline
SUA concentration increased; thus, the correlation between SUA and T2DM requires further evaluation and the baseline insulin
resistance status should also be considered.
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In 2011, there were 366 million people with dia-
betes, and this number is expected to rise to 552
million by 2030.1 The majority of the patients have
type 2 diabetes mellitus (T2DM). The prevalence of
T2DM has become a big public health challenge
worldwide. Dietary recommendations and genetic
counseling have been taken into consideration in pre-
venting the development of T2DM.2,3 However, iden-
tifying a high risk susceptible population and
encouraging lifestyle modification is likely to be the
most effective strategy of prevention. Therefore, great
efforts have been made to gain insight into T2DM risk
factors, including a strong family history of diabetes
mellitus, age, obesity, physical inactivity, body mass
index (BMI), alcohol intake, serum triglyceride con-
centration, uric acid concentration, and coronary heart
disease.4e6 Whether the above defined risk factors can
be applicable to the global community however re-
quires further investigation.7
Many recent epidemiologic evidences have been
devoted to the relationship between serum uric acid
(SUA) and T2DM. A meta-analysis of 11 studies re-
ported in 2009 revealed a positive relationship between
SUA and the development of T2DM8 but with several
limitations existed. First, the progression of T2DM
frequently occurs with aging and metabolic syndrome
(MS) factors. As a type of MS, increased SUA can also
be accompanied with T2DM.9,10 Second, several more
factors, such as fasting blood glucose (FBG), 2-hour
post prandial blood glucose (2 h-PBG), family his-
tory of diabetes, physical activity, and drugs affecting
SUA at baseline, also participate in the progression and
development of T2DM. Such factors can be con-
founding for evaluating the correlation between SUA
and T2DM. No sufficient adjustment and/or objective
quality assessment was made for these confounding
factors in the studies that included in this meta-
analysis. Third, a combination of risk ratios (RRs)
and odds ratios (ORs) as indicators of RR could have
overestimated the actual RR.Recently, a variety of publications closely exam-
ining this association showed discordant results. Thus,
the relationship between SUA and T2DM still remains
controversial. This meta-analysis also included the
most recent 5 studies since 2009 that indicated a pos-
itive relationship between SUA and T2DM, and then to
better quantify this positive correlation a literature-
based systematic review was performed.
Methods
Data selection
We conducted a computerized literature search of
the Medline, EMBASE, and PubMed databases. The
following algorithm was applied for both the Medical
Subject Heading (MeSH) and the full text. The search
strings were as follows: [(‘uric acid’ [mesh]) AND
(‘type 2 diabetes’ [mesh])] AND [‘uric acid’ AND
‘type 2 diabetes’].
Inclusion and exclusion criteria
Included articles were required to meet the
following criteria: (1) inclusion of T2DM as a
dominant outcome; (2) measurement of SUA con-
centration at baseline; (3) at baseline the participants
did not have T2DM; (4) RR or OR and its corre-
sponding 95% confidence interval (CI) or sufficient
data to calculate them were provided. The articles
were excluded if: (1) the outcome was not T2DM; (2)
the baseline SUA level was not assessed; (3) RRs or
ORs and its corresponding 95% CIs (or data to
calculate them) were not given. If data from two or
more articles were derived from the same subjects,
only the most recent article was included in this
analysis.
Data extraction
Two researchers independently screened and
assessed each of the potential titles, abstracts, and/or
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any discrepancies occurred, a third investigator would
make the definitive decision for the study eligibility
and data extraction. Data extracted for this review
included the first author's name, publication year,
population studied, baseline SUA (mg/dl), age (years),
percentage of men, sample size, number of cases,
adjusted RR (95% CI), multivariable adjustment,
cohort design, and duration of follow-up. Additionally,
the original data of baseline 2h-PBG and the subse-
quent adjustments were requested from the authors of
these primary articles included. Commitments or
questionnaires for all of the participants were admin-
istered correspondingly in each study of this meta-
analysis.
Statistical analysis
In the studies which the analyzed SUA level was
defined as a categorical variable, the pooled RR could
not be calculated directly from the different results of
the SUA stratification analysis. To quantify the dose-
response relationship between the baseline SUA level
and the development of T2DM, the RR was calculated
for the increment of 1 mg/dl SUA in each study. This
method for trend estimation was supported by Berlin
et al.11 The logarithmic relative risk model is excellent
whereas statistical properties of the linear relative risk
model are unsuitable for categorical variables.11 The
midpoint in each category was estimated by the
average of the lower and upper bound. If the highest or
the lowest category was open-ended, the interval
length at an open-ended would be assumed to be the
same as the adjacent interval. The log RR or log OR
from each study was calculated by converting the 95%
CI to its natural logarithm (width of the CI divided by
3.92).12 The estimates for men and women were syn-
thesized into a combined value using a weighting
method in each study to decrease the large heteroge-
neity across studies.
As the overestimated pooled RR is close to 1 and of
little practical importance because the total incidence
is relatively rare,8 the RRs and ORs should be evalu-
ated separately for the calculation and epidemiological
significance because the two indexes are distinct, and
this might be helpful to decrease the potential errors. In
assessing heterogeneity among studies, Cochran Q and
I2 statistics were used.13 For the Q statistic, a P value
<0.10 was considered statistically significant for het-
erogeneity; for I2, a value >50% was considered a
measure of severe heterogeneity. If P value <0.10 (I2
value >50%), the random-effects model whichDerSimonian and Laird reported was used14,15; other-
wise, the fix-effects model was conducted.
Sensitivity analysis to detect the source of hetero-
geneity was applied to calculate the overall homoge-
neity and effect size by excluding one study at a time.
The most weighted article was removed from the anal-
ysis and a meta-analysis with the remaining articles was
then conducted. Additionally, stratification analysis,
meta-regression, and multiple meta-regression were
used to assess a potential difference in distinct pop-
ulations characterized by different features, such as
gender, age, and geographical area. Only studies that
provided RRs were used in the sensitivity analysis,
stratification analysis, and meta-regression. A funnel
plot and Egger's linear regression test were used to
investigate any possible publication bias.16 All the sta-
tistical analyses were performed using STATA version
10.0 (STATA, College Station, TX, USA). A two-tailed
P value <0.05 was considered to be significant.
Results
Included and excluded articles
A total of 631 articles were retrieved from
EMBASE and 441 articles from PubMed. After
removing duplicates, 970 articles remained (Fig. 1)
whilst 948 articles were then excluded based on their
titles. Of the 22 articles remaining, 4 articles were
excluded for reasons listed in Fig. 1. Eighteen articles
were selected for further full-text review. Another 2
studies were excluded for the reasons presented in
Fig. 1. Thus, a total of 16 studies published from
January 1st 1975 to March 30th 2012 met the criteria
for inclusion in this meta-analysis and systematic
review.
Five studies (30%) reported risk prediction models
for men and women separately, one of which provided
data for men, women, and all of them together. Of the
remaining 4 articles, weighted estimates for the general
population were conducted to decrease the heteroge-
neity among studies. Data from two generations were
shown in one of the studies. Ultimately, 16 publica-
tions including a total of 27 risk prediction models
were statistically synthesized by meta-analysis.
Data request from the corresponding authors of
included articles
Subsequently, Wang et al replied and supplied a RR
adjusted for fasting plasma glucose,17 while the au-
thors of other studies did not reply.
Fig. 1. Flow chart on the articles selection process. T2DM: type 2 diabetes mellitus; UA:uric acid.
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Eight articles were prospective cohort studies and
eight were historical cohort studies. Mean baseline
SUA level of the subjects ranged from 4.0 to 8.0 mg/
ml. Mean age at baseline ranged from 41 to 64 years.Sample size per study ranged from 161 to 8688 and a
total of 67,174 participants were included (Table 1).
One study considered the effect of diuretic use, the
other four adjusted for FBG, one of which only refer-
ring to blood glucose level. However, there was no
study that considered both diuretic use and blood
Table 1
Characteristics of included studies.
First
author's
name
Publication
year
Cohort
design
Mean
baseline
SUA, mg/dl
Mean
age, years
Sample
size, n
Number
of cases
Adjusted
RR (95% CI)
Multivariable adjustment
Medalie13 1975 H 4.8 49 8688 344 1.15 (0.99e1.32)a Age, BMI, PVD, SBP, cholesterol,
hemoglobin, born in Europe,
education
Ohlson14 1988 H 5.3 50 766 47 1.27 (1.0e1.58)a Glutamic pyruvic transaminase,
blood glucose, BMI, Bilirubin, SBP,
FHD
Perry15 1995 P 6.0 50 7577 194 1.15 (0.96e1.36)a Age, BMI, prevalent coronary heart
disease, physical activity, alcohol,
smoking, SBP, high density
lipoprotein cholesterol, heart rate
Chou16 1998 H 5.8 50 654 39 1.73 (1.17e2.57)b NA
Taniguchi17 2001 P 5.2 41 6478 639 1.01 (0.94e1.09)a Age, BMI, alcohol, smoking,
physical activity, FBG, FHD
Meisinger18 2002 H Survey
Men18 5.7 52 3052 128 1.04 (0.91e1.20)a
Women18 4.0 51 3114 85 1.60 (1.34e1.91)a
Lin19 2004 H NA
Men19 8.0 49 293 27 0.85 (0.62e1.17)b
Women19 7.1 55 161 21 1.46 (1.08e1.98)b
Chien20 2008 H 5.6 54 2690 548 1.09 (1.01e1.17)a Age, BMI, alcohol, exercise, marital
status, education level, occupation,
FHD, MS
Dehghan21 2008 P 5.4 Over 55 4536 462 1.09 (1.03e1.16)a Age, sex, BMI, WC, SBP/DBP,
HDL-cholesterol
Nan22 2008 H cohort, serum creatinine, alcohol
drinking, history of hypertension,
FHD and ethnicity, fasting serum
insulin
Men22 6.6 41 1941 337 1.13 (1.05e1.23)a
Women22 5.0 42 2318 379 1.04 (0.96e1.14)a
Kramer23 2009 H 5.7 63.3 ± 8.6 566 55 1.63 (1.21e2.19)b Age, sex, BMI, diuretic use,
estimated glomerular filtration rate
Rathmann24 2009 P 5.1 ± 1.3 63.9 ± 5.4 887 93 1.70 (1.3e2.3)b Age, sex
Men24 6.3 ± 1.3 63.4 ± 5.4 449 60 1.50 (1.1e2.2)b
Women24 4.96 ± 1.3 62.9 ± 5.4 438 33 2.20 (1.3e3.9)b
Bhole25 2010 P Age, sex, BMI, alcohol consumption,
smoking, physical activity,
hypertension, blood glucose level,
blood cholesterol level, creatinine
level, serum triglyceride level
Original25 4.3 ± 1.1 45 4883 641 1.20 (1.11e1.28)a
Offspring25 5.7 ± 1.4 37 4292 497 1.15 (1.06e1.23)a
Yamada26 2011 P Age. BMI, FHD, hypertension,
triglyceride, fatty liver, alcohol,
smoking
Men26 5.97 ± 1.21 48.4 ± 10.2 7114 576 1.00 (0.92e1.09)b
Women26 4.27 ± 0.92 50.0 ± 9.1 5529 221 1.36 (1.17e1.58)b
Tiange27 2011 P 4.78 ± 1.50 61.6 924 98 1.199 (1.033e1.391)a Age, sex, BMI, FHD, smoking,
alcohol, SBP/DBP, HDL-cholesterol,
total cholesterol, triglyceride, FBG,
fasting insulin, serum creatinine,
white blood cell, high sensitive C-
reactive protein
Kai28 2011 P 5.22 ± 1.33 45e64 711 68 1.426 (1.17e1.705)a BMI, PP, PPI, SBP, heart rate, FBG,
WC, total cholesterol, HDL-C
SUA: serum uric acid; PVD: peripheral vascular disease; FHD: family history of diabetes; FBG: fasting blood glucose; HDL: high density lipo-
protein; MS: metabolic syndrome; WC: waist circumference; BMI: body mass index; SBP/DBP: systolic/diastolic blood pressure; alcohol: alcohol
consumption; PP: pulse pressure; PPI: pulse pressure index; NA: not available; H: Historical; P: Prospective.
aHR or RR; bAdjusted OR.
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Fig. 2. Forest plot of risk of T2DM for each mg/dl increase in SUA. A. Overall RR (with corresponding 95% CIs) respectively for risk of type 2
diabetes for each mg/dl increase in SUA from random effect model. Diamonds are overall relative risk; Horizontal lines indicate 95% CIs. B.
Overall OR (with corresponding 95% CIs) respectively for risk of type 2 diabetes for each mg/dl increase in SUA from fix effect model. Diamonds
are overall relative risk; Horizontal lines indicate 95% CIs.
T2DM: type 2 diabetes mellitus; SUA: serum uric acid.
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Table 2
Stratified and meta-regression analysis to explore the effects of study characteristics on T2DM.
Variable Stratum Studies (n) RR Tests for heterogeneity Meta-regression
Q P I2 (%) P
Sex Male 7 1.078 (1.031e1.127) 10.21 0.116 41.2 0.151
Female 3 1.328 (0.960e1.837) 20.98 <0.05 90.5
Geographical area Western 8 1.128 (1.094e1.163) 7.52 0.377 6.9 0.845
Asia 4 1.141 (1.018e1.279) 13.99 0.004 77.9
Age, years <50 5 1.114 (1.048e1.185) 12.40 0.015 67.7 0.865
50e60 5 1.204 (1.075e1.349) 8.16 0.086 51.0
60 2 1.115 (1.087e1.145) 1.36 0.244 26.5
SUA, mg/dl <5.5 8 1.159 (1.078e1.246) 20.9 0.004 66.5 0.832
5.5 4 1.107 (1.066e1.150) 1.7 0.637 0.0
Study design Historical 5 1.104 (1.057e1.152) 2.67 0.614 0.0 0.759
Prospective 7 1.145 (1.073e1.221) 19.82 0.003 69.7
Follow-up, years 10 7 1.083 (1.046e1.122) 7.02 0.319 14.5 0.307
>10 5 1.179 (1.100e1.264) 10.36 0.035 61.4
Adjustment
Family history of DM Yes 5 1.080 (1.040e1.120) 7.27 0.122 45.0 0.131
No 7 1.150 (1.109e1.192) 9.84 0.131 39.0
Physical activity Yes 6 1.124 (1.055e1.197) 13.44 0.094 46.9 0.661
No 6 1.113 (1.072e1.156) 9.41 0.020 62.8
FBG Yes 5 1.166 (1.064e1.279) 12.34 0.001 78.1 0.485
No 7 1.100 (1.063e1.138) 3.08 0.799 0.00
BMI Yes 10 1.139 (1.084e1.197) 21.6 0.01 58.3 0.633
No 2 1.091 (1.030e1.156) 0.59 0.444 0.00
SBP Yes 9 1.137 (1.104e1.171) 13.56 0.094 41.0 0.077
No 3 1.053 (1.000e1.109) 2.92 0.232 31.5
Alcohol Yes 7 1.115 (1.063e1.170) 13.6 0.034 55.9 0.314
No 5 1.199 (1.076e1.336) 8.87 0.065 54.9
Smoking Yes 5 1.126 (1.082e1.172) 12.4 0.015 67.7 0.917
No 7 1.126 (1.069e1.186) 10.08 0.122 40.4
TC Yes 7 1.152 (1.112e1.193) 9.87 0.13 39.2 0.074
No 5 1.074 (1.034e1.115) 5.94 0.204 32.7
WC Yes 2 1.228 (0.945e1.595) 7.20 0.007 86.1 0.579
No 10 1.115 (1.083e1.148) 15.66 0.074 42.5
Summary relative risk for the relationship between uric acid and T2DM by gender, geographical area, adjustments (family history of DM, physical
activity, FBG, BMI, SBP, alcohol, smoking, total cholesterol, waist circumference and so on), and meta regression analysis to explore the effects of
study characteristics except the analytic stratification variable. Pooled RRs of T2DM for each 1 mg/dl increase in SUAwithin the strata of each study
characteristic are indicated.
SUA: serum uric acid; DM: diabetes mellitus; FBG: fasting blood glucose; BMI: body mass index; SBP: systolic blood pressure; WC: waist
circumference; TC: total cholesterol.
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surements were adjusted for 2h-PBG or for other drugs
that influenced SUA level such as allopurinol.
Mean follow-up duration ranged from 2.0 to 62.0
years with 9 articles conducted among the European
population, and the other 7 articles were among theAsian
population. Four articles included men only, while the
rest articles included both men and women. Other rele-
vant study characteristics are tabulated in Table S1.
Results of the meta-analysis
A forest plot with RRs (95% CIs) and pooled esti-
mates of increased risk of T2DM with respect to per
1 mg/dl increase in SUA is presented in Fig. 2. Arandom-effects model showed that the pooled adjusted
RR and its 95% CI was 1.131 (1.084e1.179), and the
pooled adjusted OR and its 95% CI was 1.484
(1.278e1.723). Heterogeneity of RR and OR observed
among these studies were 51.9% (Q ¼ 22.86,
P ¼ 0.018) and 27.7% (Q ¼ 5.53, P < 0.237). The
pooled estimates were synthesized for men and women
of each study separately and that significantly
decreased the heterogeneity of RR among studies from
68.4% to 51.9% and of OR from 81.6% to 27.7%.
In the sensitivity analysis to evaluate the stability of
the relationship between SUA and T2DM, the adjusted
RR was still similar (RR ¼ 1.140, 95%
CI: 1.087e1.197), with evidence of statistically sig-
nificant heterogeneity (P ¼ 0.015, I2 ¼ 54.5%).
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region, age, confounding factors, and other study
properties relevant to study quality. For those with
previously elevated SUA, the risk of having T2DM was
attenuated by adjusting for all of the above factors (all
pooled RRs were 1). The findings were similar irre-
spective of the physical activity (P ¼ 0.661) or family
history of diabetics (P ¼ 0.131). Effect of diuretic use
was considered in only one study (RR ¼ 1.63) (Table
2). In the multiple regression analysis of confounding
factors for T2DM, the P-values of all variables
included were >0.05 (Table S2).
For young adults (18e30 years) without MS, each
unit increase in SUA was associated with increased
overall risk of type 2 diabetes (OR ¼ 1.22, 95%
CI: 1.07e1.38).18 RRs for the development of diabetes
corresponding to per mg/dl increase in SUA were 1.27
(1.06e1.52) in pre-menopausal women and 1.21
(1.09e1.35) in post-menopausal population respec-
tively.19 Whereas a relatively higher incidence of dia-
betes was found in post-menopausal hyperuricemic
women compared with pre-menopausal women
(OR ¼ 3.88, 95% CI: 1.92e7.91).
Publication bias
Significant funnel plot asymmetry for the relation-
ship between uric acid and T2DM is shown in Fig. 3.
P-value for Begg's regression test was less than 0.01,
which indicates a high risk of publication bias.
Discussion
This systematic review aimed to further qualify the
relationship between SUA and the development of
T2DM. Recently (since 2009) 5 related studies wereFig. 3. Funnel plot of cohort studies to evaluate the relationship of
serum uric acid and type 2 diabetes. Begg's regression test, P < 0.5.published. The results of this meta-analysis indicated
that each 1 mg/dl increase in SUA led to a 13.1% in-
crease in the risk of T2DM (pooled RR) and a 48.4%
increase in the risk of T2DM (pooled OR). Stratified
analysis by age, gender, geographical area, SUA, study
design, duration of follow-up, and confounding factors
further indicated that SUA was positively related with
T2DM. In addition, multiple meta-regression did not
show these variables influenced the correlation be-
tween SUA and T2DM.
The results of the previous meta-analysis published
in 2009 suggested that SUA was positively associated
with the development of T2DM.8 Several limitations of
that meta-analysis have been discussed in the Intro-
duction section of this manuscript. Given that those
limitations might influence the accuracy of results, the
methods in this study were thus improved. First, to
decrease the bias due to the combination of RRs and
ORs, here, the Meta-Analysis was conducted for RRs
and ORs separately. The estimates for men and women
from each study were synthesized by a weighting
method and further combined afterwards. The hetero-
geneity of the RR among studies decreased from 68.4%
to 51.9% and of the OR from 81.6% to 27.7%, which
should provide a more reliable summary RR. We also
have contacted the corresponding authors of each
article for complementary information about the RR
adjusted for FBG and 2h-PBG, as well as drugs
affecting SUA concentration and other confounding
factors. Despite few responses, more research should
be conducted to sufficiently assess the relationship
with the help of the authors of the articles included in
this study.
Elevated SUA predicts T2DM not only among the
young but also the elderly,18 especially the pre-
menopausal and post-menopausal women.20 Costa
et al21 described a positive association between SUA
and the development of T2DM in 2002, but did not
provide RRs or data to calculate such an association
and thus, this article was not included in our meta-
analysis. Metabolic risk factors, especially elevated
SUA, are independent predictors of diabetes and
impaired glucose tolerance (IGT) in Mauritian nor-
moglycemic subjects over 5 years of follow-up.19
However, this study provided the risk of diabetes and
IGT together and thus it was not included in our meta-
analysis either.22 Even though a positive relationship
between SUA and T2DM in these studies was pre-
sented, there is conflicting evidence on epidemiology
and on biology, presented as follows.
It has been reported that the progression of T2DM
frequently occurs with aging and MS factors and vice-
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also be paralleled by the development of T2DM. Thus,
the possibility of a correlation rather than causation
between SUA and T2DM should not be excluded. As
Cook et al23 reported, up to 8.0 mmol/L, a positive
relationship was observed between serum glucose
status and SUA concentrations whereas lower SUA
levels were observed at higher levels of glucose.
Therefore, an inverse V-shaped relationship should
also be considered. In addition, lowering SUA con-
centration could prevent nephropathy in T2DM.24e26
However, the effect of lowering SUA on the preven-
tion and treatment of T2DM is still unknown.
Biologically, as a systemic marker of oxidative
status, SUA is strongly linked to insulin resistance (a
pathogenic mechanism of T2DM) by inhibiting the
production of nitric oxide27 or increasing the expres-
sion of C-reactive protein.28 Such practice would
activate platelet adhesiveness,29,30 and induces endo-
thelial dysfunction,31 which blocks insulin-stimulated
glucose uptake. On the contrary, other studies have
reported that lowering SUA concentration might not be
an effective strategy for restoring endothelial func-
tion32,33 and might not lower the risk of development
of T2DM. Additionally, Pfister et al34 stated that SUA
is not responsible for the development of T2DM and
reported limited expectations that uric-acid-lowering
drugs will be effective in the prevention of T2DM.
The underlying mechanism of T2DM included in-
sulin resistance, hyperinsulinemia, and a variety of
metabolic abnormalities, which also might increase
SUA concentration. Hyperinsulinemia caused by in-
sulin resistance is inversely related to 24 h urinary UA
clearance35,36; insulin resistance can lead to an in-
crease in SUA concentration by both reducing renal
UA secretion by renal proximal tubular UA reabsorp-
tion enhancement in humans due to an active transport
mechanism closely linked to the tubular reabsorption
of sodium37e41 and accumulating substrates for UA
production.42 Furthermore, two studies showed that
homeostasis model assessment (HOMA) insulin resis-
tance (HOMA-IR) increased as the concentration of
SUA elevated at baseline. Chien et al43 reported
HOMA-IR was 1.48, 1.63, 1.77, 1.93, and 2.16 from
the lowest to the highest quintile of SUA. Whereas
Wang et al17 reported HOMA-IR was 0.9, 0.9, 1.3, and
1.8 from the lowest to the highest quantile of SUA
(P < 0.001). Therefore, a correlation between SUA and
T2DM should be considered.
Because of the conflicting results listed above,
further quality assessment should be arranged. First,
besides obesity, being female and elderly have beenmentioned to be major risk factors for the development
of prediabetes and T2DM,44e46 and all important
confounding factors should be adjusted for including
parental history of DM, physical activity, age, gender,
BMI, drinking, and smoking, and especially FBG/
PBG. Unfortunately, none of the included studies
adjusted adequately for all of these factors. Second,
several anti-hypertensive drugs including losartan and
hydrochlorothiazide can increase SUA concentration.
Hypertension patients with a higher SUA concentration
who are taking these drugs should be excluded. There
was only one included study47 that adjusted for diuretic
drugs and age, gender, BMI, and also estimated
glomerular filtration rate. On the contrary, adjustment
for blood pressure (BP) in 6 articles20,48e52 has a risk
of over-adjustment. Therefore, whether SUA is an
innocent bystander or a cause for T2DM needs further
exploration.
Although 4 studies19,20,51,53 demonstrated that the
association between SUA and DM was heterogeneous
for men and women, the pooled analysis showed that
the increased risk was similar for men and women.
Further investigation into the probable different cor-
relation of SUA and T2DM should be conducted be-
tween men and women instead of adjustment.
The main limitation of the present study is the sta-
tistical publication bias, because each publication step
was inevitably affected by the factors of publication
year, editors, authors, and the results found. According
to the results of the meta-regression classified by the
publication year, the reported relationship between
SUA and T2DM was significantly different at each
time. Studies with positive results are more likely to be
accepted. The possibility that studies with negative
results did not have the opportunity to be published
should also be considered.
Next, the RR calculation for per 1 mg/dl increase in
SUA to quantify the dose-response relationship be-
tween the baseline SUA level and incidence of T2DM
may have overestimated the magnitude of any publi-
cation bias.8
In conclusion, the results of this meta-analysis
indicate that SUA is independently associated with
development of T2DM, both in men and women, in the
elderly and the young, in pre-menopausal and post-
menopausal women. Insulin resistance increased as
baseline SUA concentration increased; thus, the cor-
relation between SUA and T2DM should be further
evaluated and baseline insulin resistance status should
be considered. Therefore, more evidence of the
epidemic etiology, mechanisms, and especially ge-
netics are urgently needed to further clarify whether
90 Y.-L. Xu et al. / Chronic Diseases and Translational Medicine 2 (2016) 81e91the relationship between SUA and the development of
T2DM is causal or simply a co-occurrence. In addition,
studies investigating the effect of interventions to lower
SUA concentrations in T2DM are warranted.
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